Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lonza Group AG (LONN.SW)
CHF583.00
-5.60 (-0.95%)
CH SIX Healthcare Biotechnology
Address
Muenchensteinerstrasse 38 4002
Basel, BS, CH
Basel, BS, CH
CEO
Wolfgang Wienand
Website
lonza.com
IPO
1999-11-01
ISIN CH0013841017
Also trades on
London Stock Exchange · 0QNO.L (CHF)
Other OTC · LZAGF (USD)
Other OTC · LZAGY (USD)
Swiss Exchange · LONN.SW (CHF)
Description
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF583.00
-5.60 (-0.95%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
164.1K
Beta
0.83
Float Shares
69.81M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.36% | +0.74% | +4.42% | -6.68% | -9.02% | -6.57% | -12.09% | -11.71% | -13.58% | +217.03% | +488.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
583.00
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 8 | +1 |
| Buy | 14 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.21
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-0.7% Q4'25: -18.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+51.5% ★ Q4'25: -397.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+8.0% ★ Q4'25: +2.8% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+19.3% ★ Q4'25: +19.0% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+8.2% ★ Q4'25: +14.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-1.6% ★ Q4'25: -3.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.19× Q4'25: 1.27× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 23 Rev. Ana. 17 EPS Ana. |
Dec 2027 23 Rev. Ana. 17 EPS Ana. |
Dec 2028 18 Rev. Ana. 14 EPS Ana. |
Dec 2029 11 Rev. Ana. 8 EPS Ana. |
Dec 2030 9 Rev. Ana. 12 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.45B
est.
|
2.48B
est.
|
2.38B
est.
|
2.18B
est: 2.21B (-1.3%)
|
2.52B
est: 2.48B (+1.6%)
|
2.29B
est: 2.70B (-15.5%)
|
2.87B
est: 2.89B (-0.6%)
|
2.94B
est: 2.96B (-0.8%)
|
2.69B
est: 2.76B (-2.5%)
|
2.68B
est: 2.80B (-4.3%)
|
2.69B
est: 2.67B (+0.9%)
|
3.93B
est: 3.92B (+0.2%)
|
3.58B
est: 3.80B (-5.7%)
|
3.64B
est: 3.75B (-3.0%)
|
3.80B
est: 3.80B (+0.1%)
|
4.13B
est: 4.04B (+2.3%)
|
4.55B
est: 5.11B (-11.0%)
|
5.54B
est: 5.82B (-4.7%)
|
4.21B
est: 5.90B (-28.7%)
|
4.51B
est: 6.09B (-25.9%)
|
5.41B
est: 5.20B (+4.0%)
|
6.22B
est: 6.19B (+0.5%)
|
6.72B
est: 6.70B (+0.3%)
|
6.57B
est: 6.53B (+0.7%)
|
6.53B
est: 7.56B (-13.6%)
|
7.12B
7.01B – 7.33B
-5.8% YoY
|
7.98B
7.75B – 8.19B
+12.1% YoY
|
8.98B
8.96B – 9.00B
+12.5% YoY
|
10.18B
9.95B – 10.46B
+13.3% YoY
|
11.21B
10.95B – 11.52B
+10.1% YoY
|
| EBITDA |
535.56M
est.
|
617.00M
est.
|
483.79M
est.
|
388.00M
est: 238.76M (+62.5%)
|
499.00M
est: 357.76M (+39.5%)
|
494.00M
est: 428.38M (+15.3%)
|
684.00M
est: 478.16M (+43.0%)
|
807.00M
est: 593.21M (+36.0%)
|
518.00M
est: 615.23M (-15.8%)
|
644.00M
est: 428.01M (+50.5%)
|
513.00M
est: 547.14M (-6.2%)
|
651.00M
est: 577.65M (+12.7%)
|
696.00M
est: 427.05M (+63.0%)
|
732.00M
est: 274.53M (+166.6%)
|
781.00M
est: 453.54M (+72.2%)
|
766.00M
est: 596.99M (+28.3%)
|
1.07B
est: 726.20M (+47.6%)
|
1.43B
est: 1.01B (+41.5%)
|
1.35B
est: 1.19B (+13.1%)
|
1.39B
est: 1.22B (+14.0%)
|
1.38B
est: 1.30B (+6.2%)
|
2.12B
est: 1.41B (+50.2%)
|
1.53B
est: 1.69B (-9.1%)
|
1.54B
est: 1.66B (-7.0%)
|
1.31B
est: 1.90B (-31.1%)
|
1.79B
1.76B – 1.84B
-5.8% YoY
|
2.01B
1.95B – 2.06B
+12.1% YoY
|
2.26B
2.26B – 2.26B
+12.5% YoY
|
2.56B
2.50B – 2.63B
+13.3% YoY
|
2.82B
2.76B – 2.90B
+10.1% YoY
|
| EBIT |
328.48M
est.
|
458.20M
est.
|
290.47M
est.
|
215.00M
est: 128.63M (+67.1%)
|
311.00M
est: 231.24M (+34.5%)
|
306.00M
est: 323.74M (-5.5%)
|
437.00M
est: 321.26M (+36.0%)
|
563.00M
est: 419.46M (+34.2%)
|
249.00M
est: 495.91M (-49.8%)
|
379.00M
est: 242.40M (+56.4%)
|
224.00M
est: 356.50M (-37.2%)
|
328.00M
est: 383.63M (-14.5%)
|
409.00M
est: 327.37M (+24.9%)
|
446.00M
est: 249.84M (+78.5%)
|
498.00M
est: 434.04M (+14.7%)
|
448.00M
est: 455.46M (-1.6%)
|
609.00M
est: 612.73M (-0.6%)
|
905.00M
est: 790.39M (+14.5%)
|
794.00M
est: 829.51M (-4.3%)
|
874.00M
est: 1.02B (-14.3%)
|
860.00M
est: 1.09B (-21.2%)
|
1.39B
est: 1.18B (+17.4%)
|
911.00M
est: 1.16B (-21.7%)
|
895.00M
est: 1.14B (-21.5%)
|
1.26B
est: 1.31B (-3.8%)
|
1.24B
1.22B – 1.27B
-5.8% YoY
|
1.39B
1.35B – 1.42B
+12.1% YoY
|
1.56B
1.56B – 1.56B
+12.5% YoY
|
1.77B
1.73B – 1.82B
+13.3% YoY
|
1.95B
1.90B – 2.00B
+10.1% YoY
|
| Net Income |
315.22M
est.
|
406.61M
est.
|
212.56M
est.
|
138.00M
est: 84.21M (+63.9%)
|
188.00M
est: 150.52M (+24.9%)
|
222.00M
est: 204.93M (+8.3%)
|
301.00M
est: 236.95M (+27.0%)
|
419.00M
est: 309.46M (+35.4%)
|
159.00M
est: 391.51M (-59.4%)
|
284.00M
est: 164.31M (+72.8%)
|
154.00M
est: 277.38M (-44.5%)
|
182.00M
est: 226.36M (-19.6%)
|
87.00M
est: 177.86M (-51.1%)
|
237.00M
est: 85.91M (+175.9%)
|
277.00M
est: 243.19M (+13.9%)
|
301.00M
est: 294.77M (+2.1%)
|
726.00M
est: 379.49M (+91.3%)
|
559.00M
est: 830.32M (-32.7%)
|
645.00M
est: 550.71M (+17.1%)
|
869.00M
est: 676.69M (+28.4%)
|
2.94B
est: 724.54M (+306.3%)
|
1.22B
est: 1.13B (+7.6%)
|
654.00M
est: 573.00M (+14.1%)
|
636.00M
est: 983.97M (-35.4%)
|
949.00M
est: 1.13B (-16.3%)
|
1.31B
1.17B – 1.44B
+15.2% YoY
|
1.40B
1.37B – 1.69B
+7.0% YoY
|
1.69B
1.36B – 1.95B
+20.6% YoY
|
2.10B
2.04B – 2.18B
+24.8% YoY
|
2.30B
2.24B – 2.39B
+9.5% YoY
|
| SGA |
513.12M
est.
|
546.20M
est.
|
603.06M
est.
|
116.00M
est: 185.08M (-37.3%)
|
124.00M
est: 203.97M (-39.2%)
|
130.00M
est: 216.92M (-40.1%)
|
194.00M
est: 231.61M (-16.2%)
|
324.00M
est: 333.10M (-2.7%)
|
310.00M
est: 302.02M (+2.6%)
|
307.00M
est: 314.42M (-2.4%)
|
365.00M
est: 284.05M (+28.5%)
|
544.00M
est: 536.49M (+1.4%)
|
429.00M
est: 531.61M (-19.3%)
|
519.00M
est: 434.51M (+19.4%)
|
536.00M
est: 546.91M (-2.0%)
|
732.00M
est: 587.42M (+24.6%)
|
831.00M
est: 883.80M (-6.0%)
|
1.03B
est: 850.29M (+21.4%)
|
804.00M
est: 837.39M (-4.0%)
|
703.00M
est: 932.68M (-24.6%)
|
754.00M
est: 998.63M (-24.5%)
|
827.00M
est: 1.08B (-23.5%)
|
837.00M
est: 880.90M (-5.0%)
|
945.00M
est: 864.15M (+9.4%)
|
765.00M
est: 994.23M (-23.1%)
|
936.91M
921.84M – 964.01M
-5.8% YoY
|
1.05B
1.02B – 1.08B
+12.1% YoY
|
1.18B
1.18B – 1.18B
+12.5% YoY
|
1.34B
1.31B – 1.38B
+13.3% YoY
|
1.47B
1.44B – 1.52B
+10.1% YoY
|
| EPS |
5.49
est.
|
5.52
est.
|
4.36
est.
|
2.70
est: 2.94 (-8.2%)
|
3.68
est: 3.83 (-4.0%)
|
4.34
est: 4.24 (+2.4%)
|
5.86
est: 5.72 (+2.4%)
|
8.16
est: 6.87 (+18.8%)
|
2.95
est: 4.95 (-40.4%)
|
5.14
est: 5.14 (0.0%)
|
2.76
est: 3.87 (-28.6%)
|
3.11
est: 3.99 (-22.0%)
|
1.67
est: 4.43 (-62.3%)
|
4.56
est: 5.25 (-13.2%)
|
5.30
est: 6.18 (-14.2%)
|
5.73
est: 7.63 (-24.9%)
|
9.78
est: 9.90 (-1.2%)
|
7.51
est: 11.86 (-36.7%)
|
8.73
est: 12.91 (-32.4%)
|
11.68
est: 13.45 (-13.2%)
|
39.65
est: 12.57 (+215.3%)
|
16.37
est: 14.80 (+10.6%)
|
8.88
est: 7.92 (+12.1%)
|
8.93
est: 13.98 (-36.1%)
|
13.55
est: 16.44 (-17.6%)
|
17.87
16.66 – 20.58
+8.7% YoY
|
21.29
19.47 – 24.12
+19.2% YoY
|
25.27
19.41 – 27.79
+18.7% YoY
|
29.99
29.10 – 31.07
+18.7% YoY
|
32.84
31.87 – 34.02
+9.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 4/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-168.24M
OE per share TTM
-2.60
Owner's Yield
-0.48%
Maintenance CapEx ratio
292.41%
Maint CapEx / Avg PPE
104.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
69.1K
Shares Outstanding
69.84M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wolfgang Wienand | Chief Executive Officer | 2M | — |
| Daniel Buchta | Head of Investor Relations | — | male |
| Jason Berndt | Executive Vice President & Head of Group Operations | — | male |
| Jennifer Clancy | Senior Director of Global Marketing | — | female |
| Kim Harrelson | Head of Ethics & Compliance, ERM and Corporate Responsibility | — | female |
| Andreas Bohrer | Chief Legal & Corporate Affairs Officer | — | male |
| Nicoleta Baumgartner | Chief Human Resources Officer | — | female |
| Philippe Deecke | Chief Financial Officer | — | male |
| Victoria Morgan | Head of External Communications | — | female |
| Matthias Hofmann | Head of Corporate Environment, Health, Safety & Global Sustainability | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LONN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
